BTIG analysts initiated coverage of Hims & Hers Health (NYSE:HIMS) with a Buy rating and a price target of $35 on the stock. The recommendation highlights the company's innovative approach to delivering healthcare services and its strong growth trajectory.

Hims & Hers operates a disruptive, direct-to-consumer business model, offering health services on a subscription basis to over 2 million members—a 44% year-over-year increase as of the third quarter of 2024. The company addresses a wide range of health issues, including obesity, sexual health, mental health, and dermatology, using a cash-pay approach that bypasses traditional insurance frameworks.

According to the analysts, the company’s proprietary Electronic Medical Record (EMR) system is a key strength, integrating seamlessly with its 503A and 503B affiliated pharmacies to provide a comprehensive, streamlined experience. Demand remains robust for its offerings, particularly GLP-1 and other obesity-related health products, which are expected to drive continued revenue growth.

With a well-managed business model and a strong growth profile, Hims & Hers is positioned to capitalize on evolving consumer healthcare trends. The Buy rating reflects confidence in the company’s ability to sustain its earnings power and expand its market share in the direct-to-consumer health space.